US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating ...

The phase 3 MIRASOL trial (NCT04209855) final analysis demonstrated that mirvetuximab soravtansine-gynx (Elahere; AbbVie) continued to deliver superior clinical benefits in patients with folate ...

So the MIRASOL study was meant to be a confirmatory phase III study following the SORAYA study. And this was intended to support approval globally for the use of mirvetuximab soravtansine.

Conversion to regular approval from accelerated approval was based on data from the confirmatory phase 3 MIRASOL trial (ClinicalTrials.gov Identifier: NCT04209855) which included 453 adults with ...

Results of the phase 3 MIRASOL trial also showed a similar reduction in risk for disease progression or death and a higher objective response rate with mirvetuximab soravtansine-gynx (Elahere ...

The phase 3 MIRASOL study enrolled 453 patients with high-grade serous epithelial platinum-resistant ovarian cancer whose tumors had high levels of folate receptor alpha and had received up to three ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data.

In the MIRASOL trial, 453 patients with FRα+ PROC received either mirvetuximab soravtansine (n = 227) or the investigator’s choice of single-agent chemotherapy (n = 226).

The phase 3 MIRASOL trial win makes Elahere the first medicine to show an overall survival advantage in platinum-resistant ovarian cancer, the company was quick to point out.

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

ImmunoGen, Inc. Reports Financial Results for the Quarter and Year Ended December 31, 2022 IMMUNOGEN, INC. SELECTED FINANCIAL INFORMATION (in thousands, except per share amounts) ...